IDH2 and glioblastoma: More specifically, the two patients diagnosed with glioblastomas were expected to survive about 2 years (14.8% patients) and 10 years (2.6%), Amut-IDH, sin-codel-1p/19q, G3-4, and these patients were expected to survive about 2 years (43.3%) and 10 years (19% patients), Omut-IDH, codel-1p/19q, G3, and these patients are expected to survive about 2 years (68.6% patients) and 10 years (39.3% patients).